P
ProfoundBio
An oncology biotherapeutics company
About ProfoundBio
ProfoundBio is a clinical-stage biotherapeutics startup that operates in the oncology sector. The company is dedicated to the discovery and development of novel antibody-based therapeutic agents, with a primary focus on treating a wide range of cancers. Their proprietary technology platform, which is based on Antibody-Drug Conjugates (ADCs), is at the forefront of their research and development efforts. ADCs are a type of targeted cancer therapy that delivers cytotoxic drugs directly to cancer cells, thereby minimizing damage to healthy cells.
Read full description
The company's business model revolves around the development of these novel therapies and their subsequent commercialization. ProfoundBio's revenue generation strategy is likely to be based on the sales of these therapies once they have been approved by regulatory bodies such as the FDA.
ProfoundBio's clients are primarily patients suffering from various types of cancer. The company aims to provide these patients with innovative and effective treatments that have the potential to cure their disease.
The company's team comprises experienced scientists and clinicians who adopt a creative approach to drug discovery and development. They are committed to rapidly bringing their novel therapies to patients, which could potentially give ProfoundBio a competitive edge in the fast-paced biotech industry.
At a glance
- Founded
- 2018
- Headquarters
- Woodinville, United States
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Latest news
Press, funding announcements and product moves mentioning ProfoundBio.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Chang 'an Capital
Gaorong Capital- K2K2VC
Series A18 investors entered at this stage
LYFE Capital
Lilly Asia Ventures
Oriza Holdings
HSG- CCChang'an Capital
Sequoia
Ally Bridge Group
RA Capital Management
Janus Henderson Investors
Octagon Capital Partners
T. Rowe Price- PCPiper Heartland Healthcare Capital
LifeSci Venture Partners
Nextech Invest
OrbiMed
Medicxi
Logos Capital
Surveyor Capital
Series B and later12 investors entered at this stage
- OPOctagon Capital Partners
- RA Capital Management
- LCLogos Capital
- OrbiMed
- MEMedicxi
- T. Rowe Price
- Janus Henderson Investors
- SCSurveyor Capital
- LPLifeSci Venture Partners
- AGAlly Bridge Group
- PCPiper Heartland Healthcare Capital
- NINextech Invest
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
8 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about ProfoundBio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ProfoundBio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.